Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
The European Commission approved obicetrapib products from Menarini Group and NewAmsterdam Pharma, marking the drug’s first global regulatory approval. The decision creates a commercial launch setup for NewAmsterdam while putting execution against the Phase 3 efficacy and tolerability profile into focus.
PR NEWSWIRE / FILEThe story
The European Commission approved Ubeslo, an obicetrapib monotherapy, and Evlarco, a fixed-dose combination of obicetrapib and ezetimibe, developed by Menarini Group and NewAmsterdam Pharma. The approval is supported by the Phase 3 BROADWAY, BROOKLYN and TANDEM trials, which demonstrated significant LDL-C reductions and a favorable tolerability profile.
The decision is described as the first global regulatory approval for obicetrapib and marks a regulatory milestone for both companies. It moves the program from late-stage clinical development into the commercial phase in Europe.
For NewAmsterdam, the approval connects its obicetrapib program to potential product revenue, while Menarini becomes the larger pharmaceutical partner associated with the European rollout. NewAmsterdam reported $22.5M of revenue in FY 2025, down 50.6% year over year, before this approval.
The immediate commercial outcome remains uncertain: the approval establishes the regulatory basis for the products but does not by itself provide launch sales or market-share figures. Execution, European commercialization and the products’ uptake will determine how quickly the milestone changes NewAmsterdam’s financial profile.
The next milestones are the European launch process and subsequent company updates on commercialization, prescription demand and revenue contribution.
Our read · Mon, Sep 21
NAMS won EU approval for Ubeslo and Evlarco, obicetrapib’s first global regulatory clearance.
Why. The approval gives NewAmsterdam a path from a pre-commercial program to product revenue, but the company enters that phase from FY 2025 revenue of $22.5M, down 50.6% year over year, and a -902.1% net margin. The commercial launch and the first reported uptake figures will decide whether the regulatory milestone becomes a material change in the company’s financial trajectory.
Both cases
What could change this view: A slow European launch or limited prescribing could leave the approval disconnected from near-term revenue, while NewAmsterdam’s FY 2025 losses show the funding profile remains important.
Who reported it · 1
Keep reading
Latest on the Wire
Beijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsAMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersContinue on the Wire →Latest on the Wire
Anthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackTrump Media buys back $100 million of notes ahead of Nov. 30 cash demandContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%About this report
Reported by PR Newswire, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →